Ftse Mib
38.634,23
-0,38%
DAX
23.093,90
-1,51%
S&P 500
5.738,52
-1,78%
NASDAQ
18.069,26
-2,61%
Bitcoin
89.144,09
-0,88%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Assembly Biosciences Inc (ASMB) Assembly Biosciences Inc (ASMB) Notizie

ASMB

Assembly Biosciences (ASMB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ASMB
DataOraFonteTitoloSimboloCompagnia
26/02/202514:00GlobeNewswire Inc.Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta VirusNASDAQ:ASMBAssembly Biosciences Inc
20/02/202522:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ASMBAssembly Biosciences Inc
20/02/202514:00GlobeNewswire Inc.Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital HerpesNASDAQ:ASMBAssembly Biosciences Inc
14/02/202522:58Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ASMBAssembly Biosciences Inc
31/12/202422:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ASMBAssembly Biosciences Inc
26/12/202414:00GlobeNewswire Inc.Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis BNASDAQ:ASMBAssembly Biosciences Inc
23/12/202417:59Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ASMBAssembly Biosciences Inc
19/12/202414:00GlobeNewswire Inc.Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development ProgramsNASDAQ:ASMBAssembly Biosciences Inc
14/11/202421:22Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ASMBAssembly Biosciences Inc
07/11/202422:42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ASMBAssembly Biosciences Inc
07/11/202422:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ASMBAssembly Biosciences Inc
07/11/202422:05GlobeNewswire Inc.Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent UpdatesNASDAQ:ASMBAssembly Biosciences Inc
23/09/202414:00GlobeNewswire Inc.Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366NASDAQ:ASMBAssembly Biosciences Inc
08/08/202422:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ASMBAssembly Biosciences Inc
08/08/202422:05GlobeNewswire Inc.Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent UpdatesNASDAQ:ASMBAssembly Biosciences Inc
15/07/202414:00GlobeNewswire Inc.Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus WorkshopNASDAQ:ASMBAssembly Biosciences Inc
18/06/202414:00GlobeNewswire Inc.Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus InfectionNASDAQ:ASMBAssembly Biosciences Inc
17/06/202414:00GlobeNewswire Inc.Assembly Biosciences Announces $12.6 Million in Equity FinancingsNASDAQ:ASMBAssembly Biosciences Inc
10/06/202414:00GlobeNewswire Inc.Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366NASDAQ:ASMBAssembly Biosciences Inc
05/06/202414:00GlobeNewswire Inc.Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024NASDAQ:ASMBAssembly Biosciences Inc
22/05/202414:00GlobeNewswire Inc.Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024NASDAQ:ASMBAssembly Biosciences Inc
08/05/202422:05GlobeNewswire Inc.Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:ASMBAssembly Biosciences Inc
28/03/202421:05GlobeNewswire Inc.Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent HighlightsNASDAQ:ASMBAssembly Biosciences Inc
08/02/202414:00GlobeNewswire Inc.Assembly Biosciences Announces Effective Date of Reverse Stock SplitNASDAQ:ASMBAssembly Biosciences Inc
04/01/202414:00GlobeNewswire Inc.Assembly Biosciences Provides Anticipated Development Milestones for 2024NASDAQ:ASMBAssembly Biosciences Inc
21/12/202322:06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ASMBAssembly Biosciences Inc
21/12/202322:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ASMBAssembly Biosciences Inc
11/12/202322:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ASMBAssembly Biosciences Inc
11/12/202322:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ASMBAssembly Biosciences Inc
22/11/202322:12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ASMBAssembly Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ASMB

La tua Cronologia

BOV
K1EY34
Keycorp
EU
BE0002975564
Deutschsprachige Gemeins...
EU
BTGC1
Tagus Soc Titul Creditos...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci